home

Pharma's doctor payments do pay off, with more money yielding more scripts: ProPublica

Commentscoverage2016-03-22 13:52 Read   174

Doctors deny that speaking fees, free meals, entertainment and other pharma incentives actually change their prescribing habits. They're independent, objective, too high-minded to be influenced by money.

BioMarin Phase 3 Study of Pegvaliase for Phenylketonuria (PKU) Meets Primary Endpoint of Blood Phenylalanine (Phe) Reduction

TrendBioMarin2016-03-22 13:43 Read   433

BioMarin announced today that the pivotal Phase 3 PRISM-2 study (formerly referred to as 165-302) of pegvaliase met the primary endpoint of change in blood Phe compared with placebo (p<0.0001) in preliminary results.

Valeant turns crisis into farce

TrendEP Vantage2016-03-22 13:26 Read   83

with Valeant’s stock off 60% over the past five days and its business in tatters you might have been excused for thinking that things couldn’t get much worse. You’d have been wrong.

Merck's $20M-plus Harvard deal offers a lesson on the new Economics 101 of preclinical R&D

CommentsMerck2016-03-22 13:16 Read   148

Last fall, the folks behind Harvard's Blavatnik Biomedical Accelerator took a promising preclinical program from the lab of Matthew Shair and essentially posted a "for sale" sign on it--touting its potential for mounting a fresh line of attack on acute myeloid leukemia with a counterintuitive therapeutic strategy ready for the clinic. 

A New Look At The Most Innovative Pharma Companies (And Whether They Are Sustainable) -- Part I

CommentsForbes2016-03-22 12:58 Read   368

Measuring pharma innovation isn’t easy. One typically counts new drugs approved, but that only gauges quantity not quality. Various attempts at assessing quality have been made using such criteria as new modes of action (first-in-class); therapeutic need (orphan drugs); medical value (expert panels); or improvement over the standard of care (breakthrough therapy designations).

FDA proposes ban on most powdered medical gloves

RegulatorFDA2016-03-22 10:06 Read   78

Today, the U.S. Food and Drug Administration announced a proposal to ban most powdered gloves in the United States.

CDC Issues New Guidelines To Combat Opioid Epidemic

RegulatorForbes2016-03-21 16:53 Read   88

In response to the continuing epidemic of deaths from overdoses of prescription opioids, the CDC today issued new recommendations to help prevent opioid misuse and overdose, with the goal of improving patient safety and overall care.

Therapy focus – Ovarian cancer field readies for phase III readouts

CommentsEP Vantage2016-03-21 16:14 Read   131

Ovarian cancer specialists are in for a lively few months, with a run of pivotal trial readouts, two or more filings and the outcome of an EU submission for a long-forgotten project – events that could collectively move the field forward.

AACR preview – Novel targets in the spotlight

FrontierEP Vantage2016-03-21 15:58 Read   197

The annual meeting of the American Association for Cancer Research has steadily been gaining in importance, and when its latest instalment kicks off in New Orleans next month investors will be watching particularly for initial data from novel cancer immunotherapy mechanisms.

GSK's chief executive Sir Andrew Witty to retire next year

EVENTSGSK2016-03-21 14:45 Read   124

GlaxoSmithKline has confirmed that chief executive Sir Andrew Witty intends to retire next year, leaving a position he has held since 2008.

Greg Simon Named Executive Director for the White House's Cancer Moonshot Task Force

RegulatorFriends of Cancer Research2016-03-21 14:37 Read   161

Friends of Cancer Research would like to congratulate Greg Simon on being named executive director of the White House's Cancer Moonshot Task Force.

Senate Puts Forth Legislation on FDA Centers of Excellence

Regulator Immediate Release2016-03-21 14:31 Read   76

Senator Alexander and Senator Murray for introducing the FDA and NIH Workforce Authorities Modernization Act. The Act takes several steps that will ultimately enhance cutting edge medical research.